Should You Buy Theravance Biopharma, Inc. Stock in 2026?
According to the CirclFi Deep Alpha Valuation Engine, Theravance Biopharma, Inc. (TBPH) scores a robust 8.2/10 on our 32-signal Quality of Company framework. At the current market price of $17.04 and a $885M market cap, our analysis maps this fundamental strength against 13 institutional-grade models to determine if a sufficient margin of safety exists.
The short answer: 3 of 7 CirclFi valuation models project upside for Theravance Biopharma, Inc. (TBPH) at $17.04 — the model consensus leans bearish, with a Quality Score of 8.2/10 and Value-Trap risk of 18/100. The full bull case, bear case, and risk factors are below. Educational analysis, not financial advice.
What Is the Investment Case for Theravance Biopharma, Inc. (TBPH) in 2026?
What Is the Bull Case vs the Bear Case for Theravance Biopharma, Inc. (TBPH)?
| Bull case — $49.54 target (+190.7%) | Bear case — $3.65 target (-78.6%) |
|---|---|
| According to the CirclFi Quality of Company (QOC) framework, Theravance Biopharma, Inc.'s quality score of 8.2/10 demonstrates the operational excellence that historically correlates with long-term shareholder value creation. | According to the CirclFi Deep Alpha Valuation Engine, the First Chicago model sees the stock as overvalued with a fair value of $3.65 (-78.6%), suggesting that the market price embeds overly optimistic growth assumptions. |
| According to the CirclFi Deep Alpha Valuation Engine, the RCMH-DCF model targets a fair value of $49.54 (+190.7%), anchoring the bull case with a methodology that provides a differentiated analytical lens. | According to the CirclFi Deep Alpha Valuation Engine, the wide model spread of +269.3% reflects fundamental divergence on key assumptions (growth, cost of capital) depending on the methodology. |
| Industry tailwind: breakthrough therapy designations could provide meaningful support for Theravance Biopharma, Inc.'s revenue and margin trajectory in the Biotechnology space. | Industry headwind: reimbursement uncertainty represents a meaningful risk for Theravance Biopharma, Inc. and its Biotechnology peers. |
How Does TBPH Compare to Its Biotechnology Peers?
Valuation data pages: MNKD · KROS · ACAD · TGTX · TECH · VXRT · GOVX · SLDB · INDP · EXEL · INCY
Which Other Stocks Score Like TBPH on Quality?
Closest companies to TBPH’s Quality of Company score of 8.2/10, across all industries.
- MITT — TPG Mortgage Investment Trust, Inc. (QOC 8.2) · analysis
- VRRM — Verra Mobility Corporation (QOC 8.2) · analysis
- GOLD — Gold.com, Inc. (QOC 8.2) · analysis
- KDP — Keurig Dr Pepper Inc. (QOC 8.2) · analysis
- NBBK — NB Bancorp, Inc. (QOC 8.2) · analysis
- ICFI — ICF International, Inc. (QOC 8.2) · analysis
- NVDA — NVIDIA Corporation (QOC 10.0) · analysis
Which Biotechnology Screens Does TBPH Appear In?
So Is Theravance Biopharma, Inc. (TBPH) Worth Buying in 2026?
Caution dominates our read on Theravance Biopharma, Inc. at $17.04. 4 of 7 models see limited upside or outright downside, with the median fair value at $12.09 (-29.1%). Quality at 8.2/10 provides some fundamental cushion. Current holders should re-evaluate their thesis; new buyers should demand a wider margin of safety.
These are quantitative model outputs, not investment recommendations. Theravance Biopharma, Inc.'s future depends on factors — management execution, competitive dynamics, regulatory changes — that no algorithm can fully capture. See all 13 model estimates →
What Else Do Investors Ask About TBPH Stock?
Should I buy TBPH stock right now?
Based on CirclFi's multi-model analysis, 3 of 7 models see upside for TBPH at $17.04. The models are divided, which means the investment case depends heavily on your assumptions about Theravance Biopharma, Inc.'s future. This is not a buy recommendation — see our full disclaimer.
What are the biggest risks of investing in Theravance Biopharma, Inc.?
Key risks include: limited model coverage (7/13 active), reducing analytical confidence; wide model disagreement (1258% spread), signaling high uncertainty; general market and sector-specific risks affecting Biotechnology companies. Always diversify and consult a financial advisor.
How does TBPH compare to its competitors?
Among Biotechnology peers, TBPH holds a Quality Score of 8.2/10. Comparable companies include MNKD (QOC 8.3), KROS (QOC 8.2), ACAD (QOC 8.3). The relative ranking helps investors identify whether TBPH offers better fundamental quality than alternatives in the same sector.
Is TBPH a good long-term investment?
Long-term investment potential depends on fundamental quality and sustainable competitive advantages. TBPH's Quality Score of 8.2/10 is encouraging for long-term holders, indicating consistent profitability, manageable debt, and healthy cash flows. Check our full data page for all 13 model estimates.
What price should I buy TBPH at?
CirclFi does not provide target buy prices or price alerts. However, our 7 active models produce fair value estimates ranging from $3.65 to $49.54. At $17.04, the stock trades within the range of model estimates. Many value investors look for a 20-30% margin of safety below intrinsic value before buying.
Want the complete picture?
See all 13 model estimates, confidence scores, and the full valuation table for TBPH.
Disclaimer: This article is produced by the CirclFi Valuation Engine using quantitative models and is for educational and informational purposes only. It is not financial advice, a buy/sell recommendation, or a solicitation to trade securities. Past performance is not indicative of future results. All data sourced from SEC EDGAR, FRED, and GDELT. Consult a licensed financial advisor before making investment decisions. Full disclaimer →
Buy with Gumroad